Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05327816 · ClinicalTrials.gov registry record · Phase 1
A Study of Various Respiratory Syncytial Virus (RSV) Pre-Fusion (preF)-Based Vaccine Formulations in Adults Aged 60 Years and Older
A Phase 1 study, sponsored by Janssen Vaccines & Prevention B.V..
- Terminated
- Registry status
- Phase 1
- Development phase
- 132
- Enrollment target
NCT05327816 is a Phase 1 study that was terminated before completion, run by Janssen Vaccines & Prevention B.V.. The registered enrollment target is 132 participants.
The verdict
NCT05327816, a Phase 1 study, was terminated before completion, sponsored by Janssen Vaccines & Prevention B.V..
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 132 participants
- Enrollment target
Study Summary
The purpose of the study is to evaluate safety and immunogenicity of various respiratory syncytial virus (RSV) pre-Fusion (preF)-based vaccine components followed by expanded safety evaluation and durability/revaccination evaluation of the selected RSV preF-based vaccine formulation in participants aged greater than or equal to (\>=) 60 years in stable health.
Interventions
- DRUG Placebo
- BIOLOGICAL RSV preF-based Vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 132 participants |
| Start Date | 2022-04-13 |
| Est. Completion | 2023-02-14 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05327816
The ClinicalTrials.gov registry entry for NCT05327816 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 132 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Janssen Vaccines & Prevention B.V., which has 34 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05327816 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05327816 about?
NCT05327816 is a clinical study titled "A Study of Various Respiratory Syncytial Virus (RSV) Pre-Fusion (preF)-Based Vaccine Formulations in Adults Aged 60 Years and Older". The purpose of the study is to evaluate safety and immunogenicity of various respiratory syncytial virus (RSV) pre-Fusion (preF)-based vaccine components followed by expanded safety evaluation and durability/revaccination evaluation of the selected RSV preF-based vaccine formulation in participants ...
What is the current status of trial NCT05327816?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 132 participants. The study started on 2022-04-13. Estimated completion is 2023-02-14.
What interventions are being tested in trial NCT05327816?
The interventions under investigation include: Placebo (DRUG), RSV preF-based Vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT05327816?
This trial is sponsored by Janssen Vaccines & Prevention B.V., which has 34 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.